Abstract:Introduction Small cell lung cancer (SCLC) has recently been characterized as heterogeneous tumors due to consensus nomenclature for distinct molecular subtypes on the basis of differential expression of four transcription markers (ASCL1, NEUROD1, POU2F3, and YAP1). It is necessary to validate molecular subtype classification in primary SCLC tumors by immunohistochemical (IHC) staining and investigate its relevance to survival outcomes. Methods Using a large number of surgically resected primary SCLC tumors, we assessed the mRNA and protein levels of the four subtype markers (ASCL1, NEUROD1, POU2F3 and YAP1) in two independent cohorts, respectively. Next, molecular subtypes defined by the four subtype markers was conducted to identify the association with clinicopathologic characteristics, survival outcomes, the expression of classic neuroendocrine markers, and molecules related to tumor immune microenvironment. Results Samples were categorized into four subtypes based on the relative expression levels of the four subtype markers, yielding to ASCL1, NEUROD1, POU2F3 and YAP1 subtypes, respectively. The combined neuroendocrine differentiation features were more prevalent in either ASCL1 or NEUROD1 subtypes. Kaplan-Meier analyses found that patients with tumors of the YAP1 subtype and ASCL1 subtype obtained the best and worst prognosis on both mRNA and IHC levels, respectively. Based on multivariate Cox proportional-hazards regression model, molecular subtype classification determined by IHC was identified as an independent indicator for survival outcomes in primary SCLC tumors. Correlation analyses indicated that the four subtype markers in SCLC cancer cells were interacted with its tumor immune microenvironment. Specifically, tumors positive for YAP1 was associated with fewer CTLA4 + T cell infiltration, while more immune-inhibitory receptors (FoxP3,PD1, and CTLA4) and fewer immune-promoting receptor (CD8) were found in tumors positive for ASCL1. Conclusions We validated the new molecular subtype classification and clinical relevance on both mRNA and protein levels from primary SCLC tumors. The molecular subtypes determined by IHC could be a pre-selected effective biomarker significantly influenced on prognosis in patients with SCLC, which warrants further studies to provide better preventative and therapeutic options for distinct molecular subtypes.

Molecular Classification of Small Cell Lung Cancer Subtypes: Characteristics, Prognostic Factors, and Clinical Translation

Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation

Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities

Advances in novel molecular typing and precise treatment strategies for small cell lung cancer

[Molecular Subtype of Small Cell Lung Cancer: Challenge for Transforming into Clinical Practice]

Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

Molecular Subtyping of Small-Cell Lung Cancer Based on Mutational Signatures with Different Genomic Features and Therapeutic Strategies

Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity

Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer

Characteristics of molecular subtypes and cinical outcomes in the immunotherapy Queue of extensive-stage small cell lung cancer patients

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer

Treatment of Small Cell Lung Cancer: Recent Advances

Heterogeneity of molecular subtyping and therapy-related marker expression in primary tumors and paired lymph node metastases of small cell lung cancer

Landscape and Treatment Options of Shapeshifting Small Cell Lung Cancer

Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer

Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets

Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities.

Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes